GlassScriptPhysician profile
Tiffany Ali
NPI 1083090294
$2,270.17
in general payments reported to CMS, 2019-2025
24 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $261 · 2023: $145 · 2024: $681 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $605.98 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $326.89 | 2025 | Repatha, Otezla, Otezla |
| Boston Scientific Corporation | $172.64 | 2024-2025 | Watchman Access System |
| Sumitomo Pharma America, INC. | $159.40 | 2024-2025 | Gemtesa |
| Acadia Pharmaceuticals INC | $145.32 | 2023 | Nuplazid |
| Janssen Pharmaceuticals, INC | $124.99 | 2021 | |
| Paratek Pharmaceuticals, INC. | $124.99 | 2022 | |
| Edwards Lifesciences Corporation | $121.77 | 2022 | |
| Novo Nordisk INC | $92.07 | 2024-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $71.34 | 2024-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Abbvie INC. | $35.49 | 2025 | |
| Abbott Laboratories | $32.74 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.75 | 2025 | |
| Lilly USA, LLC | $28.71 | 2025 | Kisunla |
| Inspire Medical Systems, INC. | $25.38 | 2025 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.41 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.48 | 2025 | Lifevest |
| Esperion Therapeutics, INC. | $22.33 | 2024 | Nexletol |
| Exact Sciences Corporation | $19.36 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $18.89 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $17.25 | 2025 | Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $16.88 | 2024 | |
| Eisai INC. | $15.61 | 2025 | |
| Neurocrine Biosciences, INC. | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.